Table 1.
Candida glabrata isolates, Australia: year of isolation, body site, sequence types and in vitro susceptibility to five antifungal agents.
| Isolate ID | Year isolation | Body site | ST | MIC μg/ml | ||||
|---|---|---|---|---|---|---|---|---|
| FLU | VOR | POS | AMB | CAS | ||||
| ATCC 90030 | NA | Blood | ST10 | 8 | 0.5 | 1 | 1 | 0.06 |
| WM_04.242 | 2002 | Blood | ST7 | 32 | 0.5 | NA | 0.25 | 0.06 |
| WM_03.308 | 2003 | Blood | ST7 | 8 | 0.25 | 0.125 | 0.125 | 0.008 |
| WM_03.419 | 2003 | Blood | ST83 | 128∗ | 2 | 1 | 1 | 0.008 |
| WM_03.449 | 2003 | Blood | ST26 | 64∗ | 1 | 0.5 | 0.25 | 0.25 |
| WM_03.450 | 2003 | Blood | ST83 | 32 | 0.5 | 0.5 | 0.06 | 0.25 |
| WM_03.698 | 2003 | Blood | ST7 | 32 | 1 | 0.5 | 0.06 | 0.25 |
| WM_03.707 | 2003 | Blood | ST83 | 16 | 0.25 | 1 | 1 | 0.12 |
| WM_04.113 | 2003 | Blood | ST123 | 128∗ | 2 | 2 | 0.125 | 0.125 |
| WM_04.387 | 2003 | Blood | ST7 | 32 | 0.5 | NA | 0.25 | 0.25 |
| WM_04.194 | 2004 | Blood | ST3 | 4 | 0.25 | NA | 1 | 0.25 |
| WM_05.155 | 2004 | Blood | ST126 | 16 | 0.5 | 0.5 | 0.25 | 0.03 |
| WM_05.111 | 2004 | Blood | ST55 | 32 | 1 | NA | 0.25 | 1 |
| WM_05.113 | 2004 | Blood | ST18 | 64∗ | 1 | NA | 0.25 | 0.06 |
| WM_18.26 | 2010 | Blood | ST10 | 8 | 0.12 | 0.5 | 2 | >8 |
| WM_18.24 | 2012 | Blood | ST16 | 4 | 0.06 | 0.25 | 0.5 | 8 |
| WM_18.30 | 2014 | Blood | ST3 | 16 | 0.5 | 1 | 1 | 0.25 |
| WM_18.31 | 2014 | Blood | ST45 | 1 | 0.06 | 0.12 | 0.5 | 0.03 |
| WM_18.33 | 2014 | Blood | ST7 | 128∗ | 2 | >8 | 0.5 | 0.06 |
| WM_18.36 | 2014 | Blood | ST36 | 8 | 0.25 | 1 | 1 | 0.12 |
| WM_18.39 | 2014 | Blood | ST83 | 2 | 0.03 | 0.06 | 0.5 | 0.06 |
| WM_18.40 | 2014 | Blood | ST46 | 128∗ | 2 | >8 | 1 | 0.06 |
| WM_18.41 | 2014 | Blood | ST123 | 8 | 0.25 | 1 | 0.5 | 0.12 |
| WM_18.42 | 2014 | Blood | ST123 | 256∗ | 8 | 1 | 0.25 | 0.25 |
| WM_18.43 | 2014 | Blood | ST83 | 8 | 0.25 | 1 | 1 | 0.06 |
| WM_18.44 | 2014 | Blood | ST3 | 16 | 0.5 | 2 | 1 | 0.06 |
| WM_18.45 | 2014 | Blood | ST127 | 16 | 0.25 | 1 | 0.5 | 0.06 |
| WM_18.34 | 2015 | Blood | ST3 | 16 | 0.5 | 1 | 1 | 0.06 |
| WM_18.35 | 2015 | Blood | ST3 | 4 | 0.12 | 0.25 | 0.5 | 0.03 |
| WM_18.37 | 2015 | Blood | ST22 | 16 | 0.25 | 1 | 0.5 | 0.12 |
| WM_18.38 | 2015 | Blood | ST6 | 8 | 0.25 | 1 | 1 | 0.25 |
| WM_18.47 | 2015 | Blood | ST46 | 16 | 0.25 | 0.5 | 1 | 0.25 |
| WM_18.48 | 2015 | Blood | ST83 | 32 | 1 | 2 | 1 | 0.06 |
| WM_18.27 | 2015 | Blood | ST26 | 256∗ | 8 | >8 | 1 | 0.12 |
| WM_18.29 | 2015 | Body fluid | ST10 | 4 | 0.5 | 0.5 | 0.5 | 0.06 |
| WM_18.49 | 2017 | Blood | ST26 | 256∗ | 2 | >8 | 0.5 | 0.12 |
| WM_18.50 | 2017 | Blood | ST59 | 8 | 0.25 | 1 | 1 | 0.06 |
| WM_18.51 | 2017 | Blood | ST46 | 128∗ | 2 | >8 | 1 | 0.06 |
| WM_18.52 | 2017 | Body fluid | ST16 | 4 | 0.12 | 0.5 | 0.25 | 0.12 |
| WM_18.53 | 2017 | Blood | ST123 | 128∗ | 4 | >8 | 1 | 0.12 |
| WM_18.54 | 2017 | Blood | ST26 | 0.5 | 0.03 | 0.03 | 1 | 0.25 |
| WM_18.55 | 2017 | Blood | ST3 | 8 | 0.25 | 1 | 1 | 0.25 |
| WM_18.56 | 2017 | Blood | ST22 | 32 | 0.5 | 2 | 0.5 | 0.12 |
| WM_18.57 | 2017 | Blood | ST16 | 8 | 0.5 | 2 | 0.5 | 0.12 |
| WM_18.59 | 2017 | Blood | ST3 | 16 | 1 | 2 | 0.5 | 0.12 |
| WM_18.60 | 2017 | Blood | ST3 | 8 | 0.5 | 1 | 0.5 | 0.12 |
| WM_18.62 | 2017 | Blood | ST55 | 32 | 2 | 2 | 1 | 0.06 |
| WM_18.63 | 2017 | Blood | ST8 | 2 | 0.12 | 0.25 | 0.5 | 2 |
| WM_18.64 | 2017 | Blood | ST8 | 4 | 0.12 | 0.25 | 0.5 | 2 |
| WM_18.65 | 2017 | Blood | ST83 | 64∗ | 1 | 2 | 0.5 | 0.12 |
| WM_18.66 | 2017 | Blood | ST124 | 256∗ | 8 | 2 | 0.125 | 0.25 |
| WM_18.67 | 2017 | Tissue | ST26 | 16 | 0.5 | 1 | 1 | 0.5 |
ID, identification; MIC, minimum inhibitory concentration; NA, not available; ST, sequence type (refers to the MLST sequence type). ∗Isolates that are classed as resistant to fluconazole (Clinical and Laboratory Standards Institute [CLSI], 2017a).